Volume 23 Issue 9
Sep.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(9): 1561-1564
WANG Xiujun, ZENG Lingyong, WANG Hongman. Review on the predictive value of KL-6 for the risk of pulmonary fibrosis after ARDS[J]. Chinese Journal of General Practice, 2025, 23(9): 1561-1564. doi: 10.16766/j.cnki.issn.1674-4152.004177
Citation: WANG Xiujun, ZENG Lingyong, WANG Hongman. Review on the predictive value of KL-6 for the risk of pulmonary fibrosis after ARDS[J]. Chinese Journal of General Practice, 2025, 23(9): 1561-1564. doi: 10.16766/j.cnki.issn.1674-4152.004177
shu

Review on the predictive value of KL-6 for the risk of pulmonary fibrosis after ARDS

doi: 10.16766/j.cnki.issn.1674-4152.004177

  • Department of Respiratory and Critical Care Medicine, the Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical University, Zhuhai, Guangdong 519100, China

Funds:

 81960023

  • Received Date: 2024-09-27
    Available Online: 2025-11-17
    Abstract
  • Acute respiratory distress syndrome (ARDS) is a severe respiratory failure with a high degree of mortality. The molecular mechanism is complex, often involving multiple injuries in the lungs and the body and interactions. The main clinical features of ARDS include inflammatory response, massive release of cytokines and activation and dysregulation of coagulation pathways. Clinically, the convenient prognosis of such patients usually shows different degrees of pulmonary fibrosis, which is also an important factor leading to the poor prognosis of ARDS patients. Inflammatory response plays an important role in ARDS, including downregulation of the proinflammatory pathway and upregulation of anti-inflammatory pathways. Pulmonary fibrosis is the abnormal collagen deposition caused by continuous inflammatory damage and repair disorders, which promotes the occurrence of fibrosis. Fibrosis is a pathological process that is associated with scarring and fibrosis of the lung tissue, often accompanied by inflammation and injury. Studies have shown that the Krebs von den Lungen-6 (KL-6) high-molecular-weight mucin-like glycoprotein is closely related to the degree of alveolar epithelial damage and is a sensitive marker reflecting the degree of fibrosis. In ARDS patients, KL-6 was found to be elevated in ARDS and its subsequent pulmonary fibrosis, however, the kinetics and prognostic significance of KL-6 have not been extensively studied, and this paper focuses on the predictive role of KL-6 in pulmonary fibrosis after ARDS.

     

    • FullText(HTML)
  • loading
    • References(48)
  • [1]
    MEYER N J, GATTINONI L, CALFEE C S. Acute respiratory distress syndrome[J]. Lancet, 2021, 398(10300): 622-637. doi: 10.1016/S0140-6736(21)00439-6
    [2]
    BOS L D J, WARE L B. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes[J]. Lancet, 2022, 400(10358): 1145-1156. doi: 10.1016/S0140-6736(22)01485-4
    [3]
    ZHANG T, SHEN P, DUAN C, et al. KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis[J]. Front Immunol, 2021, 12: 745233. DOI: 10.3389/fimmu.2021.745233.
    [4]
    HE J, ZHANG J, REN X. Krebs von den lungen-6 as a clinical marker for hypersensitivity pneumonitis: a meta-analysis and bioinformatics analysis[J]. Frontiers in Immunology, 2022, 13: 1041098. DOI: 10.3389/fimmu.
    [5]
    HE Y Q, ZHOU C C, YU L Y, et al. Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms[J]. Pharmacol Res, 2021, 163: 105224. DOI: 10.1016/j.phrs.2020.105224.
    [6]
    YE C, XU B, YANG J, et al. Mucin1 relieves acute lung injury by inhibiting inflammation and oxidative stress[J]. Eur J Histochem, 2021, 65(4): 3331. DOI: 10.4081/ejh.2021.3331.
    [7]
    XIE R, TAN D, LIU B, et al. Acute respiratory distress syndrome (ARDS): from mechanistic insights to therapeutic strategies[J]. MedComm, 2025, 6(2): e70074. DOI: 10.1002/mco2.70074.
    [8]
    唐敏, 李娜. 急性呼吸窘迫综合征发病机制及相关生物标志物的研究进展[J]. 中国现代医学杂志, 2022, 32(5): 1-6.

    TANG M, LI N. Pathophysiological mechanism of acute respiratory distress syndrome and research progress on diagnostic biomarkers of ARDS[J]. China Journal of Modern Medicine, 2022, 32(5): 1-6.
    [9]
    YU H, LIU S, WANG S, et al. The involvement of HDAC3 in the pathogenesis of lung injury and pulmonary fibrosis[J]. Front Immunol, 2024, 15: 1392145. DOI: 10.3389/fimmu.2024.1392145.
    [10]
    FANG X Z, LI M, WANG Y X, et al. Mechanosensitive ion channel Piezo1 mediates mechanical ventilation-exacerbated ARDS-associated pulmonary fibrosis[J]. J Adv Res, 2023, 53: 175-186. doi: 10.1016/j.jare.2022.12.006
    [11]
    PIAZZA O, SCARPATI G, BOCCIA G, et al. KL-6 in ARDS and COVID-19 patients[J]. Transl Med UniSa, 2022, 24(2): 12-15.
    [12]
    GRASSELLI G, CALFEE C S, CAMPOROTA L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies[J]. Intensive Care Med, 2023, 49(7): 727-759. doi: 10.1007/s00134-023-07050-7
    [13]
    MOKRÁ D. Acute lung injury: from pathophysiology to treatment[J]. Physiol Res, 2020, 69(Suppl 3): S353-S366.
    [14]
    谢仁雪, 李有霞, 秘乐, 等. HMGB1及相关信号通路在急性呼吸窘迫综合征后肺纤维化中的研究进展[J]. 重庆医学, 2023, 52(11): 1748-1752, 1760.

    XIE R X, LI Y X, MI L, et al. Research progress of HMGB1 and its signaling pathway in the pulmonary fibrosis after acute respiratory distress syndrome[J]. Chongqing Medicine, 2023, 52(11): 1748-1752, 1760.
    [15]
    BATTAGLINI D, FAZZINI B, SILVA P L, et al. Challenges in ARDS definition, management, and identification of effective personalized therapies[J]. J Clin Med, 2023, 12(4): 1381. DOI: 10.3390/jcm12041381.
    [16]
    BHARAT A, HOETZENECKER K. Lung transplantation for acute respiratory distress syndrome[J]. Thorac Surg Clin, 2022, 32(2): 135-142. doi: 10.1016/j.thorsurg.2022.01.005
    [17]
    KOHNO N, AKIYAMA M, KYOIZUMI S, et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma[J]. Jpn J Clin Oncol, 1988, 18(3): 203-216.
    [18]
    INAGAKI Y, XU H, NAKATA M, et al. Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers[J]. Biosci Trends, 2009, 3(6): 220-232.
    [19]
    D'ALESSANDRO M, BERGANTINI L, CAMELI P, et al. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review[J]. Biomark Med, 2020, 14(8): 665-674. doi: 10.2217/bmm-2019-0545
    [20]
    KOHNO N, INOUE Y, HAMADA H, et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9[J]. Int J Cancer Suppl, 1994, 8: 81-83.
    [21]
    WANG Y, CHEN S, LIN Z, et al. Imaging and serum biomarkers in connective tissue disease-associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels[J]. Ann Rheum Dis, 2019, 78(4): 573-575. doi: 10.1136/annrheumdis-2018-214098
    [22]
    MOSTAFA A I, SALEM A E, AHMED H A M, et al. Role of Krebs von den Lungen-6 (KL-6) in assessing hypersensitivity pneumonitis[J]. Tuberc Respir Dis(Seoul), 2021, 84(3): 200-208. doi: 10.4046/trd.2020.0122
    [23]
    D'ALESSANDRO M, GANGI S, PAGGI I, et al. Diagnostic performance of CLEIA versus FEIA for KL-6 peripheral and alveolar concentrations in fibrotic interstitial lung diseases: a multicentre study[J]. J Clin Lab Anal, 2024, 38(19-20): e25108. DOI: 10.1002/jcla.25108.
    [24]
    JI Y, BOURKE S J, SPEARS M, et al. Krebs von den Lungen-6 (KL-6) is a pathophysiological biomarker of early-stage acute hypersensitivity pneumonitis among pigeon fanciers[J]. Clin Exp Allergy, 2020, 50(12): 1391-1399. doi: 10.1111/cea.13744
    [25]
    WANG C, WANG Q, LIU T, et al. Krebs von den Lungen-6 (KL-6) as a diagnostic marker for pulmonary fibrosis: a systematic review and meta-analysis[J]. Clin Biochem, 2023, 114: 30-38. doi: 10.1016/j.clinbiochem.2023.01.010
    [26]
    JIANG D, XIAO H, DONG R, et al. Krebs von den Lungen-6 levels in untreated idiopathic pulmonary fibrosis[J]. Clin Respir J, 2022, 16(3): 234-243. doi: 10.1111/crj.13475
    [27]
    D'ALESSANDRO M, CONTICINI E, BERGANTINI L, et al. Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease[J]. Tissue Cell, 2024, 90: 102516. DOI: 10.1016/j.tice.2024.102516.
    [28]
    MILLAN-BILLI P, CASTELLVÍ I, MARTINEZ-MARTINEZ L, et al. Diagnostic value of Krebs von den Lungen (KL-6) for interstitial lung disease: a European prospective cohort[J]. Arch Bronconeumol, 2024, 60(6): 350-355. doi: 10.1016/j.arbres.2024.03.028
    [29]
    HAN L, WANG S, MA J, et al. Expression and significance of serum KL-6 in patients with acute respiratory distress syndrome[J]. J Thorac Dis, 2023, 15(12): 6988-6995. doi: 10.21037/jtd-23-1787
    [30]
    BENEGAS URTEAGA M, RAMÍREZ RUZ J, SÁNCHEZ GONZÁLEZ M. Idiopathic pulmonary fibrosis[J]. Radiologia Vol, 2022, 64(3): 227-239.
    [31]
    D'ALESSANDRO M, BERGANTINI L, CAVALLARO D, et al. Krebs von den Lungen-6 as disease severity marker for COVID-19 patients: analytical verification and quality assessment of the Tosoh AIA-360 compared to Lumipulse G600Ⅱ[J]. Int J Environ Res Public Health, 2022, 19(4): 2176. DOI: 10.3390/ijerph19042176.
    [32]
    GORMAN E A, O'KANE C M, MCAULEY D F. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management[J]. Lancet, 2022, 400(10358): 1157-1170. doi: 10.1016/S0140-6736(22)01439-8
    [33]
    ASCHNER Y, CORRELL K A, BEKE K M, et al. PTPα promotes fibroproliferative responses after acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2022, 323(1): L69-L83. doi: 10.1152/ajplung.00436.2021
    [34]
    RAMASAMY S, SUBBIAN S. Critical determinants of cytokine storm and type Ⅰ interferon response in COVID-19 pathogenesis[J]. Clin Microbiol Rev, 2021, 34(3): e00299-20. DOI: 10.1128/CMR.00299-20.
    [35]
    LAMERS M M, HAAGMANS B L. SARS-CoV-2 pathogenesis[J]. Nat Rev Microbiol, 2022, 20(5): 270-284. doi: 10.1038/s41579-022-00713-0
    [36]
    马刚, 冯珂, 马汉宁, 等. 方舱医院新冠肺炎普通型患者临床和CT特征与住院时间关系的研究[J]. 中华全科医学, 2021, 19(2): 316-319. doi: 10.16766/j.cnki.issn.1674-4152.001798

    MA G, FENG K, MA H N, et al. A study on the relationship between clinical and CT features and length of stay of general type novel coronavirus pneumonia patients in mobile cabin hospital[J]. Chinese Journal of General Practice, 2021, 19(2): 316-319. doi: 10.16766/j.cnki.issn.1674-4152.001798
    [37]
    HAN X, FAN Y, ALWALID O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia[J]. Radiology, 2021, 299(1): E177-E186. doi: 10.1148/radiol.2021203153
    [38]
    MOHAMMADI A, BALAN I, YADAV S, et al. Post-COVID-19 pulmonary fibrosis[J]. Cureus, 2022, 14(3): e22770. DOI: 10.7759/cureus.22770.
    [39]
    KATTNER S, SUTHARSAN S, BERGER M M, et al. Serum KL-6 as a candidate predictor of outcome in patients with SARS-CoV-2 pneumonia[J]. J Clin Med, 2023, 12(21): 6772. DOI: 10.3390/jcm12216772.
    [40]
    SCARPATI G, BALDASSARRE D, BOFFARDI M, et al. Krebs von den Lungen 6 (KL-6) levels in COVID-19 ICU patients are associated with mortality[J]. J Anesth Analg Crit Care, 2022, 2(1): 37. DOI: 10.1186/s44158-022-00064-5.
    [41]
    D'ALESSANDRO M, BERGANTINI L, CAMELI P, et al. Serial KL-6 measurements in COVID-19 patients[J]. Intern Emerg Med, 2021, 16(6): 1541-1545. doi: 10.1007/s11739-020-02614-7
    [42]
    LIN H, LIU Q, ZHAO L, et al. Circulating pulmonary-originated epithelial biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis[J]. Int J Mol Sci, 2023, 24(7): 6090. DOI: 10.3390/ijms24076090.
    [43]
    ARNOLD D T, DONALD C, LYON M, et al. Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks[J]. PloS One, 2021, 16(4): e0249607. DOI: 10.1371/journal.pone.0249607.
    [44]
    PARK M, HUR M, KIM H, et al. Usefulness of KL-6 for Predicting clinical outcomes in hospitalized COVID-19 patients[J]. Medicina, 2022, 58(10): 1317. DOI: 10.3390/medicina58101317.
    [45]
    ISHIZAKA A, MATSUDA T, ALBERTINE K H, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome[J]. Am J Physiol Lung Cell Mol Physiol, 2004, 286(6): L1088-L1094. doi: 10.1152/ajplung.00420.2002
    [46]
    KONDO T, HATTORI N, ISHIKAWA N, et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome[J]. Respir Res, 2011, 12: 32. DOI: 10.1186/1465-9921-12-32.
    [47]
    ZHU W, LIU C, TAN C, et al. Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis[J]. Heliyon, 2024, 10(1): e23543. DOI: 10.1016/j.heliyon.2023.e23543.
    [48]
    LI X N, LIN Y P, HAN M M, et al. Modulating fibrotic mechanical microenvironment for idiopathic pulmonary fibrosis therapy[J]. Adv Mater, 2024, 36(50): e2407661. DOI: 10.1002/adma.202407661.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (13) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return